Linked Life Data

6384507

Source:http://linkedlifedata.com/resource/pubmed/id/6384507

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1984-11-21
pubmed:abstractText
Thymopentin (TP-5), the active side of thymopoietin, was shown to affect immunoregulation. The effect of this drug in the treatment of rheumatoid arthritis (RA) was evaluated. Three trials were performed: a six month double-blind trial comparing TP-5 administered subcutaneously to placebo at 3 different dosages, an open longterm study in which the same dosage of the drug was administered subcutaneously, and a shortterm (3 weeks) double-blind trial in which the drug was given intravenously at a high dosage (100 mg/day). In none of these 3 studies were statistically significant improvements registered in the TP-5 treated patients, although there were important improvements in individual patients. Serious side effects were not encountered, but the majority of patients did not improve or were withdrawn because of ineffectiveness. The beneficial effect of TP-5 on the clinical evolution of RA, reported elsewhere, could not be confirmed by these studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0315-162X
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
462-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
pubmed:publicationType
Journal Article, Comparative Study